Clinical Trial Update: Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a peptide vaccine to prevent acquired resistance in patients with advanced ALK-positive non-small cell lung cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ALK-positive NSCLC peptide vaccine

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1, Phase 2 | Status: RECRUITING